Answers are grounded in this paper and cite their sources.
Editorial on the Research TopicAdvances in primary immunodeficiencies (inborn errors of immunity) in Central-Eastern Europe, volume II Knowledge of Primary Immunodeficiencies (PIDs) or Inborn Errors of Immunity (IEI)has expanded exponentially during the last 20 years.New and improved diagnostic tools, including new generation sequencing (NGS), and gene product activity or functional tests have led to profound advances in clinical immunology.These advances have made it easier to understand the mechanisms and pathogenesis of different types of IEI, and subsequently to introduce targeted therapies.They help define and recognize the increasing number of IEIs.It is worth noting the tremendous role of the International Union of Immunological Societies (IUIS) and its Expert Committee in updating the categorization of IEI approximately every 2 years.According to the last report in 2022, 485 different genetic defects causing IEI are known (55 novel compared to the 2019 report), previously categorized into 10 groups and published as phenotypical classification as well.Taking into account that number of all IEIs remains underestimated, the efforts of enthusiastic clinicians and scientists to improve diagnostics, recognition, and treatment are of great value (1-3).Much of this progress in the field of clinical and experimental immunology has been made in recent decades, mainly in western Europe, the USA, Japan, and Australia (1-5), with significant contributions also coming from Latin America, Africa, the Middle East, and both South and East Asia.Eastern and Central European (ECE) countries were isolated for many years, until the fall of the iron curtain in 1989, with limited access to the newest scientific achievements, diagnostic tools, and therapeutic methods.Only personal
No takes yet. Share an insight, caveat, or question.
Pac et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: